Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating insulin resistance: future prospects.

Clifford J Bailey1

  • 1Deabetes Research Group, School of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK. c.j.bailey@aston.ac.uk

Diabetes & Vascular Disease Research
|May 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiorenal effects of therapies for type 2 diabetes and obesity.

The British journal of cardiology·2026
Same author

Metformin: Antidiabetic actions from cells to tissues.

Metabolism: clinical and experimental·2026
Same author

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

Peptides·2026
Same author

Pharmacological therapies for type 2 diabetes: future approaches.

Diabetologia·2025
Same author

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

Peptides·2025
Same author

Diabetes and gout: another role for SGLT2 inhibitors?

Therapeutic advances in endocrinology and metabolism·2024
Same journal

Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.

Diabetes & vascular disease research·2026
Same journal

Hemoglobin A1c association patterns with cardiovascular outcomes among patients with diabetes mellitus following percutaneous coronary intervention: A systematic review.

Diabetes & vascular disease research·2026
Same journal

Diabetes mellitus and abdominal aortic aneurysm growth: Clinical evidence and mechanistic insights.

Diabetes & vascular disease research·2026
Same journal

Sex differences in cardiovascular disease risk in type 1 diabetes: The vascular bed paradox in women.

Diabetes & vascular disease research·2026
Same journal

Serum LINC00861: A novel biomarker for diabetic nephropathy diagnosis and a promoter of renal injury via miR-378a-3p.

Diabetes & vascular disease research·2026
Same journal

Corrigendum to "A novel approach to diabetes-related foot ulcers/disease: First report of bipolar conventional RF lumbar sympathetic block".

Diabetes & vascular disease research·2026
See all related articles

Insulin resistance involves multiple signaling defects. Research explores various therapeutic targets and compounds, including insulin mimetics and agents enhancing insulin receptor activity, to improve metabolic and vascular functions.

Area of Science:

  • Metabolic research
  • Pharmacology
  • Molecular biology

Background:

  • Insulin resistance stems from defects in insulin receptor and post-receptor signaling pathways.
  • These defects impair crucial metabolic and vascular functions.
  • Numerous potential therapeutic targets and compounds have been identified.

Purpose of the Study:

  • To review current therapeutic strategies for insulin resistance.
  • To highlight novel approaches targeting insulin receptor and downstream signaling.
  • To discuss the potential for broad-spectrum therapeutic interventions.

Main Methods:

  • Review of existing literature on insulin resistance mechanisms and treatments.
  • Analysis of studies demonstrating therapeutic potential of various compounds.

Related Experiment Videos

  • Exploration of signaling pathway modulation strategies.

    • Main Results:

    • Non-peptide insulin mimetics show promise through direct insulin receptor activation.
    • Agents enhancing insulin receptor tyrosine kinase activity, like phosphatase inhibitors, potentiate insulin action.
    • Modulating phosphatidylinositol 3-kinase and addressing signaling defects from cytokines, hormones, and metabolic factors are viable approaches.

    Conclusions:

    • Multiple therapeutic avenues exist for insulin resistance, targeting various signaling defects.
    • Compounds like hormones, enzymes, minerals, and co-activators exhibit insulin-sensitizing potential.
    • The multifaceted nature of insulin resistance allows for simultaneous therapeutic interventions across metabolic and cardiovascular fronts.